Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced braf v600e mutation

HIGHLIGHTS

• who: Pei Meng from the Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, the Netherlands have published the article: Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation, in the Journal: (JOURNAL)
• what: The authors report treatment efficacy in two cases with acquired BRAF V600E mutations. One of the two patients included in the study had brain metastases, and the main clinical deterioration under treatment came from progression of brain metastases.
• future: To define the most . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.